Background Dominant biliary strictures occur commonly in patients with primary sclerosing cholangitis (PSC), who have a high risk of developing cholangiocarcinoma (CC). The natural history and optimal management of dominant strictures remain unclear, with some reports suggesting that endoscopic interventions improve outcome.
Introduction
During the course of primary sclerosing cholangitis (PSC), localized, high-grade (dominant) strictures may develop de novo or may be superimposed on diffuse ductal disease, resulting in impaired biliary drainage with clinical consequences including pruritus, jaundice and recurrent cholangitis. The prevalence of dominant strictures in PSC is approximately 36-56% [1] [2] [3] . Biochemical and clinical improvements have been reported after stenting and/or balloon dilatation of dominant strictures [1, [4] [5] [6] [7] [8] . Also, there is some evidence that relief of biliary obstruction can reverse secondary liver fibrosis [9] . However, most endoscopic studies of patients with PSC have been relatively small and nonrandomized, with a short-term follow-up, and other studies report a lack of biochemical responses and worse survival in patients with dominant stricture who had undergone endoscopic therapy [2, 10] . It remains unproven whether endoscopic therapy improves the long-term outcome in patients with dominant strictures.
PSC is strongly associated with cholangiocarcinoma (CC), which often arises at the site of dominant strictures [11] . In theory, successful endoscopic therapy, by delaying the need for transplant referral, may delay the diagnosis and increase the risk of an unresectable malignancy. For this reason, some have advocated early referral for transplantation in PSC patients with dominant strictures, although this remains controversial.
The aim of this retrospective review was to compare the outcome of a large series of patients with PSC with and without dominant biliary strictures managed at a single tertiary referral centre over a 25-year period, with a particular emphasis on the safety and efficacy of endoscopic therapy.
Patients and methods

Patient population
Data collection was conducted in accordance with the local guidelines and ethics approval (06/Q0152/106). From January 1984 to March 2011, patients with a suspected diagnosis of PSC attending University College London Hospitals NHS Foundation Trust were identified using computerized clinical and endoscopy databases of over 14 000 endoscopic retrograde cholangiopancreatography (ERCP) performed during the 25-year study period. The medical records were reviewed to obtain demographic, clinical, laboratory and follow-up data.
The diagnosis of PSC was made on the basis of published clinical, laboratory and cholangiographic findings [12] . In patients who underwent liver biopsy, normal findings did not preclude the diagnosis of PSC. Patients with secondary sclerosing cholangitis and those with IgG4-related cholangitis were excluded. Those with localized strictures of the extrahepatic biliary tree or right and left hepatic ducts amenable to therapeutic intervention were included in a dominant stricture group. Patients with diffuse disease including intrahepatic strictures above the main right and left hepatic ducts but without tight narrowing of the main ducts were assigned to a no dominant stricture group. Patients with small duct PSC were rare in our referral base and were not included in the study.
Standard biochemistry and, where available CA19-9, were recorded closest to the time of PSC and/or CC diagnosis. ERCP films and other imaging were reassessed wherever possible. Patients were reviewed in the clinic or, if not in regular contact with the hospital, the GP and/or patients were contacted by telephone.
Entry into the study was recorded from the time of the first cholangiogram that showed features of PSC. Endpoints were death, liver transplantation, last clinical contact or the end of the study on 1 March 2011. Death registry data were collected through the UK General Register Office (http://www.gro.gov.uk).
Endoscopic techniques
All patients received prophylactic antibiotics before ERCP, as per departmental policy. In the early part of the series, ERCPs were performed in both symptomatic and asymptomatic patients to establish the diagnosis of PSC. Since 2000, magnetic resonance cholangiopancreatography largely replaced diagnostic ERCP, although ERCP was still performed if the results of magnetic resonance cholangiopancreatography were inconclusive. The presence of dominant strictures usually prompted ERCP for tissue acquisition and endoscopic therapy by stricture dilatation and/or biliary stenting, at the discretion of the endoscopist.
Most patients in the early part of our series were treated with biliary stent insertion (usually 10 Fr straight plastic stents) replaced at approximately 6-monthly intervals or earlier if there was evidence of stent dysfunction. Previous biliary dilatation was performed where necessary to aid stent insertion using over-the-wire biliary dilating catheters up to 10 Fr in diameter or using 4-12 mm biliary dilating balloons. Stenting was only discontinued if strictures were considered to be widely patent on repeat ERCP. Subsequent clinical symptoms and liver biochemistry were observed, with stenting repeated if jaundice or cholangitis developed. In later years, some patients were treated with biliary dilatation alone if the stricture was considered to have opened successfully following dilatation. Patients with jaundice or cholangitis in whom ERCP was unsuccessful were treated with percutaneous transhepatic drainage (PTD).
Data collection and analysis
Patients with dominant strictures were defined as above. CC was diagnosed using a combination of suggestive clinical and radiographic findings plus confirmatory cytopathology/histopathology. Child-Pugh, MELD, UKELD and Mayo PSC risk scores were calculated where possible using blood results closest to the time of diagnosis. Differences in patient characteristics and endoscopic findings were assessed using the Mann-Whitney U-test or Student t-test as appropriate. A P value of less than 0.05 was considered statistically significant for all tests.
Survival was determined using the Kaplan-Meier method both from the time of PSC diagnosis and from the first visit to our unit until death, and/or time to liver transplantation or study closure. Significance values for differences in survival were compared using the log-rank test.
Results
Patient characteristics
A total of 128 patients with a confirmed diagnosis of PSC were included for analysis. The median age at PSC diagnosis was 49 years (range 13-86 years), with men being diagnosed at a similar age to women. Sixty-four per cent were men and 36% were women. The mean followup was 9.8 years (median 9 years, range 0.1-27.4 years). Of the 92 patients (72%) with a final diagnosis of inflammatory bowel disease, ulcerative colitis was present in 86%, Crohn's disease in 9% and indeterminate colitis in 5%.
At the time of referral to our institution, which has a specialist interest in biliary disease and endotherapy, 96% of patients had been symptomatic, mostly with right upper quadrant pain, jaundice or cholangitis. Two per cent of the patients (asymptomatic at the time of referral for ERCP) did not undergo repeat ERCP during the follow-up period after the index ERCP at the referring hospital.
The demographic and clinical data of patients with and without dominant strictures are presented in Table 1 . Twenty patients (16%) had documented pancreatic duct abnormalities, primarily reported to be changes of chronic pancreatitis. The median values for the PSC Mayo risk score (1.05 vs. 0.12, P = 0.026), MELD score (9.0 vs. 6.06, P = 0.009) and UKELD scores (46.6 vs. 44.0, P r 0.001) were significantly worse in the dominant stricture group compared with the no dominant stricture group ( Fig. 1 ).
Seventy patients (55%) had undergone a liver biopsy. Of these, 44% were reported as stage 0, 14% as stage I, 23% as stage II, 7% as stage III and 12% as stage IV. Twentynine patients (23%) had biopsy-proven and/or clinically overt cirrhosis (52% Child A, 27% Child B and 21% Child C). Of these, 11 (9%) developed ascites and four patients (3%) had variceal bleeding.
Documentation of the use of ursodeoxycholic acid (UDCA) was available for 102 patients, of whom 54% had used UDCA during the study period, mostly at a low dose of 5-10 mg/kg. There was a trend towards more patients in the dominant stricture group having been prescribed UDCA (60 vs. 42%, P = NS). There was no significant difference in survival in those treated with UDCA.
Endoscopic interventions and effect of dominant strictures
A total of 553 ERCPs were performed in the 128 patients, with a median of two ERCPs (range 0-23) per patient. Of these, 453 (82%) were performed at our institution, of which 443 (98%) were interventional (for tissue sampling and/or endotherapy in patients with jaundice, elevated liver function tests and/or cholangitis).
In all, 80 patients (62.5%) were found to have dominant strictures (dominant stricture group) and underwent 474 ERCPs during the follow-up period, of which 392 procedures (83%) were performed at our centre. The remaining 48 patients were classified as not having dominant strictures (no dominant stricture group) and underwent 79 ERCPs. Dominant strictures were primarily located in the common bile duct in 47 (59%), common hepatic duct in 11 (14%) and the hilum in 22 patients (27%). In those who underwent liver biopsy, the stage of PSC liver disease was significantly higher in the dominant stricture group (median stage III) compared with those without dominant stricture (median stage I, P r 0.001).
Patients with dominant biliary strictures had a median of 3 (range 0-34) therapeutic endoscopic interventions, compared with 0 (range 0-7) in the 48 without dominant strictures (P < 0.001). Therapeutic endoscopic interventions to strictures included the following: (i) stenting alone (46%), (ii) dilatation alone (20%), (iii) dilatation and stenting (17%) and (iv) no or failed intervention (17%), of whom 53% required PTD. Common bile duct or intrahepatic stones were an indication for endoscopic Complications of ERCP in the dominant stricture group included two minor (guide wire) bile duct perforations not requiring surgery and two episodes of pancreatitis, one requiring admission for more than 10 days with pseudocyst intervention and one documented episode of severe cholangitis. This corresponds to an identified serious adverse event rate of 5/453 or 1%. Several other patients will have had mild or subclinical cholangitis or pancreatitis but because of the routine use of antibiotics for up to 5 days after ERCP, varying periods of hospitalization for other reasons and retrospective data collection, the incidence of these complications could not be determined accurately. However, no patients required blood transfusions after ERCP, and there were no deaths resulting from endoscopic interventions.
During the study period, 26 of the 128 patients (20%) underwent 37 percutaneous drainage procedures (range 1-3) at our centre. Of these, 21 patients (81%) were in the dominant stricture group, and required one or more PTDs for failed ERCP access or failure to adequately drain strictures. Nine (43%) of these patients had CC with complex biliary strictures. Percutaneous transhepatic choledochoscopy with or without electrohydraulic lithotripsy to fragment intraductal stones was performed in four patients with dominant strictures.
Serious PTD-related complications included the development of a hepatocutaneous fistula in a patient who had multiple PTD's for anastamotic biliary structuring following a Whipples procedure for ampullary carcinoma complicating his PSC disease, one of which was complicated by a common bile duct perforation following PTD tract dilatation and choledochoscopy to investigate recurrent disease. Two patients had minor bile duct leaks following PTD, both of which resolved with satisfactory biliary drainage. The incidence of mild complications was difficult to quantify retrospectively but included cholangitis, minor bleeding (not requiring blood transfusion) and pain. A multivariate analysis was performed to identify the possible independent predictors of death. This confirmed predictable poor prognostic indicators such as the Mayo PSC risk score, older age, presence of CC and variceal bleeding. Interestingly, elevated alkaline phosphatase and lower haemoglobin were also independent predictors of death, but the liver biopsy stage, MELD and UKELD scores, and individual parameters of these scores (i.e. bilirubin, creatinine, prothrobin time and sodium) were not. The number of ERCP interventions or percutaneous drains was also not a significant predictor of death. The mostly negative results from multivariate analysis are likely to be because of the relatively small numbers included in this study, but do suggest a low predictive power of disease models as discussed later. Similarly, in view of the small numbers in each group, the fact that many patients had different endoscopic treatment modalities (e.g. dilatation and stenting) and the retrospective nature of the study, the effect of specific endotherapies in terms of survival and quality of life in those with dominant strictures or the subgroup with jaundice, cholangitis and/or pruritis could not be assessed accurately. However, the data suggest a nonsignificant trend towards a poorer outcome in those with benign dominant strictures, most of whom had undergone multiple endoscopic interventions directed towards stricture therapy.
Cholangiocarcinoma
Twenty-one patients (14 men, seven women) developed proven CC during the follow-up period. All occurred in patients with dominant strictures, with no CC developing in those without dominant strictures (P r 0.001). The frequency of CC during follow-up in the dominant stricture group was 21 out of 80 (26%). Jaundice and abnormal liver biochemistry were the presenting features in 19 (90%). Two patients (10%) presented with pain.
The median time from the diagnosis of PSC to CC was 26 months (range 0-246 months). Ten cases (48%) presented within 4 months of the diagnosis of PSC. In these cases, CC was most likely the reason for clinical presentation in previously unidentified PSC and so it is impossible to identify pre-existing dominant strictures, although all tumours developed stenoses in locations compatible with dominant strictures. Thereafter, the incidence of CC was approximately 1% per year. The main tumour sites were reported to be the common bile duct (43%), the common hepatic duct (9%) and the hilum (48%). All patients had died from their disease by the end of the study. The median time from the diagnosis of CC to death was 6 (1-23) months. There were no peripheral intrahepatic tumours in our series. In addition to those who developed CC, one patient developed a fatal ampullary carcinoma and another had fatal gallbladder cancer, yielding an overall frequency of biliary tract cancer of 23/128 (18%).
Patients with CC and those with benign dominant strictures were compared. CA19-9 was measured in only 43 patients (34%). The mean CA19-9 was 8236 IU/l (9-84 000 IU/ml) in those with CC and 97 IU/l (1-2640 IU/ml) with benign dominant stricture (P = 0.26). Including all those with biliary tract cancer (CC, ampullary and gallbladder cancer, n = 14) compared with those with PSC and no malignancy where the CA19-9 was measured (n = 29), the sensitivity and specificity of CA19-9 (cut-off 37 IU/ml) for the diagnosis of malignancy were 86 and 59%, respectively. The mean scores for disease models at the diagnosis of CC were significantly higher than those with benign dominant stricture for the Mayo PSC risk score (1.66 vs. 0.82, P = 0.04) and the UKELD score (50.40 vs. 47.04, P = 0.02), but not for the MELD score (11.32 vs. 8.82, P = 0.06).
Of the patients considered for surgical resection, all were excluded because of the presence of advanced PSC, peritoneal metastases at staging laparoscopy, Bismuth III or IV strictures considered unsuitable for curative surgery or being medically unfit for surgery. One patient with potentially resectable disease was found to have a synchronous nonresectable renal cell carcinoma.
Survival
Overall, 57 of the 128 patients (45%) died during followup, at a median age of 65 (range 23-93) years and a median of 57 (range 0-316) months after the diagnosis of PSC. Overall predicted survival by the Kaplan-Meier method was 17.7 years (95% confidence intervals 15.3-20.1 years) (Fig. 2) .
Models of disease stage were significantly higher for deceased patients using the Mayo risk score (median 1.39 vs. 0.02, P < 0.001) and the UKELD score (median 44.79 vs. 47.6, P = 0.04), but were not significantly different using the MELD score (6.1 vs. 8.5, P = 0.06), which tended to be higher in those patients who remained alive (Fig. 1) .
The causes of death were CC (37%), liver failure (21%), variceal bleeding (5%), other cancers (12%), ischaemic heart disease (4%), other causes (12%) and not known (9%). Forty-three deaths (75%) occurred in those with dominant strictures. Survival was significantly worse in those with dominant strictures compared with those without dominant strictures (13.7 vs. 23.0 years, P = 0.01). However, after excluding those who developed CC, the trend in worse outcome for those with benign dominant strictures compared with those without dominant strictures was no longer significant (17.5 vs. 23.0 years, P = 0.15).
Deceased patients had a higher median bilirubin (34 mmol/l) and ALP (494 IU/ml) compared with those still alive (bilirubin 16 mmol/l, P = 0.002 and ALP 269 IU/ml, P r 0.001). Other simple laboratory parameters were similar between the two groups. There was no significant difference in the rates of those taking UDCA in either group (49% dead and 58% alive).
Deceased patients had undergone more ERCP interventions than surviving patients (median 3 vs. 1, P = 0.009) Eight patients developed other notable cancers: two colorectal cancers, pancreatic cancer, ampullary cancer, gallbladder cancer, hepatocellular carcinoma, nonsmall cell-lung cancer and adenocarcinoma of unknown primary.
Nineteen patients were referred for liver transplant assessment, of whom six underwent transplantation. Of the remaining 13 patients, one patient declined, four patients were considered too well for transplantation (all alive at the end of the study period) and eight were considered unsuitable (comorbidity n = 6, coexistent malignancy n = 2) and died within a year of referral for transplantation.
Discussion
The results of several nonrandomized studies have indicated that patients with dominant PSC strictures benefit from an endoscopic intervention, with 5-year liver transplantation-free survival rates of 81-94%, compared with 65-78% predicted by the Mayo clinic model [1, 7, 8] .
In an early prospective study of 32 PSC patients with dominant strictures treated with short-term stent insertion, pruritis improved in 83% of patients, serum bilirubin reverted to normal in 12 of the 14 patients (86%) who were initially jaundiced and only 40% of patients required an additional endoscopic intervention during 3 years of follow-up [13] . In a retrospective study of 71 patients, balloon dilatation without stenting was associated with fewer intervention-related complications or cholangitis than percutaneous or endoscopic stenting, whereas there was no significant difference between the two groups with respect to cholestasis [6] . An extension of a prospective study in Germany included 171 patients with PSC treated with UDCA followed for a median of 7 years. A subset of 96 patients with major duct stenoses was subjected to repeated endoscopic dilatation with almost no biliary stents inserted. The observed long-term survival of this subset was significantly higher than that predicted with the Mayo model or historical controls (mostly undergoing stent insertion), suggesting a possible benefit of endoscopic therapy with balloon dilatation [1, 8] . A smaller earlier study from Indianapolis (n = 63), in which dominant stenoses were also treated primarily by repeated endoscopic balloon dilatation, reported very similar actuarial 5-year survival rates free of liver transplantation of 83% compared with survival rates predicted by the Mayo clinic model of 65% [7] .
These results indicate that endoscopic therapy is beneficial in patients with dominant biliary strictures. The optimal frequency and type of intervention, or the degree to which endoscopic intervention delays or obviates the need for liver transplantation, remain unclear.
Despite the lack of well-powered randomized-controlled trials, on the basis of the current accepted practice, it may be considered unethical to allow patients with dominant biliary strictures to be left untreated. However, randomized trials of dilatation versus short-term stenting are ethical and feasible. A multicentre European study to address this question has been initiated recently (http:// www.clinicaltrials.gov, NCT01398917). Current European and American guidelines advise that stricture dilatation should be undertaken as the treatment of choice for dominant strictures [14, 15] . The present study suggests that patients with dominant strictures, who have undergone repeated therapeutic biliary interventions, have worse outcome than those without dominant strictures. The predominant reason for this appears to be an increased incidence of CC in this group, with the trend in poorer outcome in the dominant stricture group becoming nonsignificant after excluding those who developed CC. Another retrospective study of 125 patients also failed to show improved outcome or liver biochemistry in patients with dominant strictures undergoing endoscopic therapy [2] . A prospective study, which included patients with dominant strictures who had undergone endoscopic therapy to dilate strictures, also reported a significantly worse transplant-free survival in those with dominant strictures, compared with those without dominant strictures (25 vs. 73%, P = 0.011) [10] . These studies indicate a poorer outcome in patients with dominant strictures despite repeated endoscopic therapy.
There are a number of potential reasons for the differences in the outcomes between trials. This may reflect a lack of significant clinical or long-term benefit from endoscopic therapy, with outcomes of small low powered studies simply reflecting expected statistical variation. There may have been a referral bias related to our specialist interest in endoscopic therapy, whereas those with more advanced parenchymal disease may have been referred directly to a transplant centre. Other reasons include variations in the treatment interventions between centres, with some studies suggesting better outcomes with stricture dilatation without long-term stenting, whereas in our series, we have historically treated the majority of patients with routine stent insertion [6] . Microbiological studies of bile from patients undergoing liver transplantation report a 58% positive culture rate, with an inverse relationship between infection rate and time from last ERCP and high rates of bactobilia (98%) in those with a biliary stent in situ compared with 55% in those without a stent [16, 17] . More recent studies suggest that the rates of clinically overt cholangitis may also be lower in those treated with biliary dilatation without stent insertion [1] . However, the most likely reason for the poorer outcome is that patients with dominant strictures have more severe parenchymal liver damage that cannot be entirely prevented or reversed by endoscopic therapy, reducing any clinical benefit of endoscopic therapy.
An obvious weakness of our study is that it is a descriptive retrospective study rather than a randomized-controlled trial. Not all of our cholangiograms were available for review. Also, descriptions of the extent and severity of biliary strictures vary and few clinicians report these in terms of proposed systematic classifications [18] . Consequently, the nature and severity of strictures reported in our series are partly subjective.
Accurate reporting of complications on the basis of historical data is difficult, but our data suggest that the complications of ERCP are fewer than that often quoted to patients on the basis of guidelines and published literature, including a prospective study addressing the question of interventional ERCP in patients with PSC suggesting a complication rate as high as 14% [19] . ERCP, in our experience, had a major complication rate of only 1%, which is comparable with the overall complication rate (mild to severe) of 5% in a large UK-wide prospective audit of all general ERCP practice [20] . This agrees with the relatively low ERCP complication rate reported in a recent large German series [1] .
Many published studies compared the observed outcomes with those predicted by historical controls using the Mayo PSC model. Advances in medical and endoscopic therapy are likely to lead to a bias in treatment and clinical outcomes towards an improved outcome with modern medical care. Therefore, the study groups are not directly comparable with the data predicted by the Mayo model. Also, our data suggest that scoring systems such as the Mayo PSC score may be indicators of outcome in patients with PSC, but are weak indicators of outcome when comparing subgroups with and without dominant strictures, suggesting that impaired parenchymal liver function is more important than the presence of complex dominant strictures when predicting outcome. Scoring systems, such as the Mayo PSC score, MELD and UKELD models, should be reserved for monitoring of disease progression and assisting with the timing of referral for liver transplantation.
The frequency of CC observed in our cohort (approximately 16%) is similar to that reported by others. There is a marked difference in the incidence of CC developing in areas with and without dominant strictures (26 and 0%, respectively). This pattern was found by others [10] . As with other series, we report a high rate of CC identified within a year of diagnosis of PSC, and in fact, half of these were identified within 4 months of the diagnosis of PSC. The incidence thereafter was approximately 1% per year in those with dominant strictures. The high rate of CC (particularly at presentation) highlights the difficult clinical problem of differentiating malignant from benign dominant biliary strictures and indicates the need for improved diagnostic tests such as genomic studies and fluorescence in-situ hybridization analysis, which has been shown to improve the diagnostic accuracy of biliary cytology sampling [21, 22] . Those with new presentations of PSC with evidence of a dominant stricture should undergo a thorough evaluation to exclude the presence of superimposed CC, with consideration of a full range of diagnostic tests at the time of ERCP, including exfoliative cytology, intraductal biopsy and cholangioscopy.
In general, the risk of cancer in any premalignant condition increases with the duration of the underlying condition, and the retrospective series of patients undergoing transplantation for PSC report background ERCP experience in PSC Chapman et al. 1057 dysplasia in 36% of patients without cancer increasing to 83% of those with coexistent CC in distant areas of the liver [23] . If endoscopic therapy was to improve the survival of patients with PSC, then it may carry the potential to increase the risk of patients developing CC before being considered for liver transplantation, although a multicentre, case-control study did not identify previous endoscopic therapy to be a risk factor for developing CC in patients with PSC [7] .
Conclusion
Our data indicate that endoscopic therapy is safe in patients with PSC, but despite repeated therapeutic endoscopic interventions, the outcome of patients with dominant strictures remains poor and the risk of developing CC in this subgroup is high.
